-
1 Comment
Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd is currently in a long term uptrend where the price is trading 10.4% above its 200 day moving average.
From a valuation standpoint, the stock is 32.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.5.
Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd's total revenue rose by 41.2% to $72M since the same quarter in the previous year.
Its net income has increased by 14.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 260.6% to $13M since the same quarter in the previous year.
Based on the above factors, Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd gets an overall score of 5/5.
Exchange | SHE |
---|---|
CurrencyCode | CNY |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
ISIN | CNE100002CP5 |
Market Cap | 3B |
---|---|
Beta | 0.53 |
PE Ratio | 102.89 |
Target Price | None |
Dividend Yield | None |
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD researches, develops, produces, and sells Chinese patent medicines, health food, and APIs in China and internationally. The company offers Xuanfei Zhicough mixture, Yuanhu Zhitong dropping pills, Qiwei Wenyang capsules, Maxing cough capsule, and Astragalus Angelica capsules. Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD was founded in 2002 and is based in Lanzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300534.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025